Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Santarsieri A, Mitchell E, Pham MH, Sanghvi R, Jablonski J, Lee-Six H, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, Ardeshna KM, Baxter J, Behan S, Bhuller K, Booth S, Chavda ND, Collins GP, Culligan DJ, Cwynarski K, Davies A, Downing A, Dutton D, Furtado M, Gallop-Evans E, Hodson A, Hopkins D, Hsu H, Iyengar S, Jones SG, Karanth M, Linton KM, Lomas OC, Martinez-Calle N, Mathur A, McKay P, Nagumantry SK, Phillips EH, Phillips N, Rudge JF, Shah NK, Stafford G, Sternberg A, Trickey R, Uttenthal BJ, Wetherall N, Zhang XY, McMillan AK, Coleman N, Stratton MR, Laurenti E, Borchmann P, Borchmann S, Campbell PJ, Rahbari R, Follows GA. Santarsieri A, et al. Among authors: follows ga. Lancet Oncol. 2025 Jan;26(1):98-109. doi: 10.1016/S1470-2045(24)00598-9. Epub 2024 Dec 12. Lancet Oncol. 2025. PMID: 39674188 Free article.
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: follows g. Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487-1. Online ahead of print. Leukemia. 2024. PMID: 39627506 No abstract available.
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.
Barrett A, Shah N, Chadwick A, Burns D, Burton C, Cutter DJ, Follows GA, McKay P, Osborne W, Phillips E, Wilson MR, Collins GP. Barrett A, et al. Among authors: follows ga. Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19840. Online ahead of print. Br J Haematol. 2024. PMID: 39506502
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Munir T, et al. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. N Engl J Med. 2024. PMID: 38078508 Clinical Trial.
Transverse Leukonychia (Mees' Lines).
Follows AM, Follows GA. Follows AM, et al. Among authors: follows ga. N Engl J Med. 2023 Nov 30;389(22):e48. doi: 10.1056/NEJMicm2304533. Epub 2023 Nov 25. N Engl J Med. 2023. PMID: 38009615 No abstract available.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP. Niemann CU, et al. Among authors: follows ga. Lancet Oncol. 2023 Dec;24(12):1423-1433. doi: 10.1016/S1470-2045(23)00452-7. Epub 2023 Nov 6. Lancet Oncol. 2023. PMID: 37944541 Clinical Trial.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin MD, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Niemann CU, Kater AP. Munir T, et al. Among authors: follows g. J Clin Oncol. 2023 Jul 20;41(21):3689-3699. doi: 10.1200/JCO.22.02283. Epub 2023 Jun 6. J Clin Oncol. 2023. PMID: 37279408 Free PMC article.
118 results